ArticleBlood cancer journal2021

ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine.

Nora E Rahmani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.